The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is
now challenging the entire lupus community, from geneticists to clinical investigators …

Systemic lupus erythematosus (SLE) is a worldwide chronic autoimmune disease which
may affect every organ and tissue. Genetic predisposition, environmental triggers, and the …

Our objective was to update the EULAR recommendations for the management of systemic
lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic …

The B cell activating factor (BAFF), or B lymphocyte stimulator (BLyS), is a B cell survival
factor which supports autoreactive B cells and prevents their deletion. BAFF expression is …

Systemic lupus erythematosus (SLE) is characterized by multisystem immune-mediated
injury in the setting of autoimmunity to nuclear antigens. The clinical heterogeneity of SLE …

Objective The role of interferon‐α (IFNα) in the pathogenesis of systemic lupus
erythematosus (SLE) is strongly supported by gene expression studies. The aim of this study …

Systemic lupus erythematosus (SLE) is characterized by immune system dysfunction and is
clinically heterogeneous, exhibiting renal, dermatological, neuropsychiatric, and …

Antinuclear antibodies (ANAs) are a diverse group of autoantibodies that recognize nuclear
macromolecules and their complexes. ANAs represent key biomarkers in the evaluation of …

The B cell-stimulating molecules, BAFF (B cell activating factor) and APRIL (a proliferation-
inducing ligand), are critical factors in the maintenance of the B cell pool and humoral …

Objectives To evaluate the efficacy and safety of tabalumab, a human IgG4 monoclonal
antibody that neutralises membrane and soluble B-cell activating factor (BAFF). Methods …